Business Wire

LähiTapiola Deploys Guidewire InsuranceSuite to Support Strategic Development

9.10.2018 12:00:00 EEST | Business Wire | Press release

Share

The LähiTapiola Group, Finnish mutual group of companies, and Guidewire Software, Inc. (NYSE:GWRE), provider of the industry platform general insurers rely upon, today announced that LähiTapiola is deploying Guidewire InsuranceSuite™. LähiTapiola is one of the leading Non-Life insurance companies in Finland. The InsuranceSuite implementation will support them in streamlining and rationalizing multiple, overlapping core systems as well as strengthening customer service and product delivery.

LähiTapiola is gradually replacing its current legacy systems in three phases. All Non-Life new business will be run on InsuranceSuite and existing business will be migrated, starting with its Private lines of insurance.

“Following an extensive vendor search LähiTapiola selected Guidewire based on their strong reputation and credibility, the usability of their software, and Proof of Concept results,” said Mikko Vastela, CIO, LähiTapiola. “As part of our strategic programme, and enabled through our InsuranceSuite deployment, we will have a renewed core system suite that can deliver a range of efficiencies and improvements in user experience both for internal and external users.”

Guidewire InsuranceSuite is enabling LähiTapiola to:

  • Improve cost efficiency by harmonizing and automating operational processes;
  • Provide new systems functionality through modern processes and interfaces; and
  • Proactively deliver simpler, more flexible products to enhance customer service, and support increased acquisition and retention.

“With InsuranceSuite we will be able to provide an improved customer experience with more tailored products and services,” commented Christine Dahlman, Program Director, LähiTapiola. “We will also be better positioned to respond to developing insurance needs and generate a competitive advantage for our business.”

“We congratulate LähiTapiola on their initial deployment and look forward to continuing our work together,” said Sheridon Glenn, vice president, Field Consulting, EMEA, Guidewire Software. “The effort to transform their core systems and offer modern products and services to their customers is in keeping with their stated corporate goals. We are honoured to contribute to this endeavour.”

About Guidewire InsuranceSuite

Guidewire InsuranceSuite is a complete set of core systems and complementary modules combined to form the ideal technology platform that delivers on supporting your critical requirements, for all lines of business, while promoting sales, service, and underwriting excellence across your organization. Guidewire InsuranceSuite is a proven solution that has helped insurers worldwide significantly enrich customer and agent/broker relationships while simultaneously growing profitably and enabling agile responses to market threats and opportunities. InsuranceSuite provides a complete set of systems to support your core operations—underwriting, policy administration, billing, and claims management—to deliver the technology you need to successfully and continually advance your products, processes, and customer relationships. InsuranceSuite’s comprehensive components are built on a common platform, Guidewire InsurancePlatform™, that covers the entire insurance lifecycle while providing the deep functionality required for you to adapt and succeed in a time of rapid industry change.

About LähiTapiola

LocalTapiola Group is a mutual group of companies owned by its customers. LocalTapiola's mission is to safeguard its owner-customers' lives and success. Our vision is to offer Finnish people a safer and healthier life. The lifelong security concept means comprehensive and proactive services. LocalTapiola serves private customers, farmers, entrepreneurs, corporate customers, and organisations.

The number of owner-customers is approximately 1.6 million. The Group consists of 20 regional mutual insurance companies, as well as the national companies, LocalTapiola General, LocalTapiola Life, LocalTapiola Asset Management, and LocalTapiola Real Estate Asset Management. LocalTapiola employs approximately 3,400 people, half of whom work in the regional companies.

www.lahitapiola.fi/localtapiola

About Guidewire Software

Guidewire delivers the industry platform that general insurers rely upon to adapt and succeed in a time of accelerating change. We provide the software, services, and ecosystem to enable our customers to run, differentiate, and grow their business. We are privileged to serve more than 350 general insurers in 32 countries. For more information, please visit https://www.guidewire.com. Follow us on twitter: @Guidewire_PandC.

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LähiTapiola
Christine Dahlman, +358405073599
Program Director
christine.dahlman@lahitapiola.fi
or
onechocolate Communications
Daniel Couzens, +44 (0)20 7437 0227
guidewire@onechocolatecomms.co.uk
or
Guidewire Software (UK) Ltd
Louise Bradley, +44 (0)7474 837 860
lbradley@guidewire.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye